Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Clinical carbapenemase producing K. pneumoniae from Alaska

PROVIDER: PRJNA622828 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11472894_1.fastq.gz	Fastqsanger.gz
	SRR11472894_2.fastq.gz	Fastqsanger.gz
	SRR11472895_1.fastq.gz	Fastqsanger.gz
	SRR11472895_2.fastq.gz	Fastqsanger.gz
	SRR11472896_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Whole transcriptomic analysis of mechanisms of tolerance and resistance to chlorhexidine in carbapenemase-producing Klebsiella pneumoniae clinical strains

Project description:The increasing resistence and/or bacterial tolerance to bactericides, such as chlorhexidine, causes worrisome public health problems. Using transcriptomical and microbiological studies, we analysed the molecular mechanisms associated with the adaptation to chlorhexidine in two carbapenemase-producing strains of Klebsiella pneumoniae belonging ST258-KPC3 and ST846-OXA48.

2020-03-21 | GSE147316 | GEO

Project description:Clinical carbapenemase-producing Klebsiella pneumoniae isolate

| PRJNA957334 | ENA

K. pneumoniae clinical isolates

Project description:Genome sequence of carbapenemase producing K. pneumoniae clinical isolates

| PRJEB37309 | ENA

Project description:Genome sequence of carbapenemase producing K. pneumoniae clinical isolates

| PRJNA613777 | ENA

Project description:Carbapenemase producing E. coli from Alaska gulls

| PRJNA521419 | ENA

Characterization of plasmids mediating carbapenem resistance in Klebsiella pneumoniae in Pretoria, South Africa

Project description:The study aimed to characterize plasmids mediating carbepenem resistance in Klebsiella pneumoniae in Pretoria, South Africa. We analysed 56 K. pneumoniae isolates collected from academic hospital around Pretoria. Based on phenotypic and molecular results of these isolates, 6 representative isolates were chosen for further analysis using long reads sequencing platform. We observed multidrug resistant phenotype in all these isolates, including resistance to aminoglycosides, tetracycline, phenicol, fosfomycin, floroquinolones, and beta-lactams antibiotics. The blaOXA-48/181 and blaNDM-1/7 were manily the plasmid-mediated carbapenemases responsible for carbapenem resistance in the K. pneumoniae isolates in these academic hospitals. These carbapenemase genes were mainly associated with plasmid replicon groups IncF, IncL/M, IncA/C, and IncX3. This study showed plasmid-mediated carbapenemase spread of blaOXA and blaNDM genes mediated by conjugative plasmids in Pretoria hospitals.

2019-10-17 | GSE138949 | GEO

Clinical Evaluation of Advanced MALDI-TOF MS for Carbapenemase Subtyping in Gram-negative Isolates

Project description:The spread of carbapenemase-producing Enterobacterales (CPE) is emerging as a significant clinical concern in tertiary hospitals and in particular, long-term care facilities with deficiencies in infection control. This study aims to evaluate an advanced matrix-assisted laser desorption/ionization mass spectrometry (A-MALDI) method for the identification of carbapenemases and further discrimination of their subtypes in clinical isolates. The A-MALDI method was employed to detect CPE target proteins. Enhancements were made to improve detectability and mass accuracy through the optimization of MALDI-TOF settings and internal mass calibration. A total of 581 clinical isolates were analyzed, including 469 CPE isolates (388 KPC, 51 NDM, 40 OXA, and 2 GES) and 112 carbapenemase-negative isolates. Clinical evaluation of the A-MALDI demonstrated 100% accuracy and precision in identifying all the collected CPE isolates. Additionally, A-MALDI successfully discriminated individual carbapenemase subtypes (KPC-2 or KPC-3/4; OXA-48 or OXA-181 or OXA-232; GES-5 or GES-24) and also differentiated co-producing carbapenemase strains (KPC & NDM; KPC & OXA; KPC & GES; NDM & OXA), attributed to its high mass accuracy and simultaneous detection capability. A-MALDI is considered a valuable diagnostic tool for accurately identifying CPE and carbapenemase’s subtypes in clinical isolates. It may also aid in selecting appropriate antibiotics for each carbapenemase subtype. Ultimately, we expect that the A-MALDI method will contribute to preventing the spread of antibiotic resistance and improving human public health.

2024-11-25 | PXD046179 | Pride

Clinical Evaluation of Advanced MALDI-TOF MS for Carbapenemase Subtyping in Gram-negative Isolates

2024-11-26 | PXD058284 | Pride

Carbapenemase Producing Organisms

Project description:Clinical Carbapenemase Producing Organism Genomic Surveillance

| PRJNA1030769 | ENA

Project description:Clinical carbapenemase/AmpC-producing Enterobacterales isolates

| PRJNA763348 | ENA